Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis

Murphy, S. M., Jeng, P. J., McCollister, K. E., Leff, J. A., Jalali, A., Shulman, M., Lee, J. D., Nunes, E. V., Novo, P., Rotrosen, J., & Schackman, B. R. (2021). Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis. Addiction (Abingdon, England), 116(12), 3444–3453. https://doi.org/10.1111/add.15531

Authors:
Sean M. Murphy
Philip J. Jeng
Kathryn E. McCollister
Jared A. Leff
Ali Jalali
Matisyahu Shulman
Joshua D. Lee
Edward V. Nunes
Patricia Novo
John Rotrosen
Bruce R. Schackman
Affiliated Authors:
Matisyahu Shulman
Edward V. Nunes
Columbia Affiliation:
Author Keywords:
buprenorphine–naloxone
cost-effectiveness
efficiency
extended-release naltrexone
induction
opioid detoxification
opioid use disorder
elink
Publication Type:
Article
Unique ID:
10.1111/add.15531
PMID:
33950535
DOI:
10.1111/add.15531
Journal:
Addiction
Publication Date:
Data Source:
Scopus
Source Link:
View Scopus Record

Record Created: